Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neuromodulation in Depression
| 対象疾患 | Major Depressive Disorder |
|---|---|
| 相 | 該当なし |
| スポンサー | Stanford University |
| ステータス | 完了 |
| 参加者数 | 50 名 |
| 介入(薬剤) | Neuronavigated rTMS, Sham rTMS |
| 開始日 | 2023年1月1日 |
| 完了日 | 2025年3月27日 |
| 結果公開日 | 2026年7月15日 |
概要
Depression is a highly prevalent condition characterized by persistent low mood, energy, and activity that can affect one's thoughts, mood, behavior, and sense of well-being. Repetitive transcranial magnetic stimulation (rTMS), a non-invasive neuromodulatory technique, is an effective treatment for depression when targeting the dorsolateral prefrontal cortex (dlPFC) of the central executive network (CEN). However, remission rates are suboptimal and individual methods to target the dlPFC are lacking. In this study, we will enroll 50 patients with major depression and in a single rTMS 'dose,' prospective, randomized, double-blind, cross-over design will assess whether rTMS targeted to an individual's central executive network (CEN) assessed by single pulse TMS can enhance network modulation. If successful, this work will lead to a clinical rTMS trial comparing this personalized targeting approach against standard rTMS.
Change in TMS-evoked EEG Responses Following Intermittent Theta Burst Stimulation (iTBS)
| Neuronavigated rTMS | 4.28 ± 0.58 dBμV |
|---|---|
| Sham rTMS | 3.95 ± 0.48 dBμV |
| Neuronavigated rTMS | 3.92 ± 0.53 dBμV |
| Sham rTMS | 4.28 ± 0.64 dBμV |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- CBT+ for Depression — University of Wisconsin, Madison
- Severe Asthma, MepolizumaB and Affect: SAMBA Study — University Hospital Southampton NHS Foundation Trust
- Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for — Levomecor Inc.
- A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major De — Levomecor Inc.
- Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders — Massachusetts General Hospital
- Individualized Functional Connectivity Targeting in aiTBS for Depression — Brigham and Women's Hospital